Mesoblast (MEOBF) News Today $1.54 0.00 (0.00%) As of 08/19/2025 Add Compare Share Share Headlines Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock MEOBF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy RatingAugust 17 at 2:27 AM | finance.yahoo.comMesoblast Limited (MESO) Launches First Cell Therapy for ChildrenJuly 28, 2025 | finance.yahoo.comJPMorgan Chase & Co. Reduces Stake in Mesoblast LimitedJuly 24, 2025 | tipranks.comMesoblast Limited Announces Quotation of New Securities on ASXJuly 14, 2025 | tipranks.comMesoblast Limited Announces Cessation of SecuritiesJuly 14, 2025 | tipranks.comJPMorgan Acquires Substantial Stake in Mesoblast LimitedJuly 6, 2025 | tipranks.comMesoblast Aligns with FDA for Revascor Biologics License ApplicationJune 30, 2025 | tipranks.comJPMorgan Chase & Co. Reduces Stake in Mesoblast LimitedJune 25, 2025 | tipranks.comJPMorgan Chase & Co. Ceases to be Substantial Holder in Mesoblast LimitedJune 15, 2025 | tipranks.comMesoblast Advances FDA Approvals for Revascor® and Ryoncil®June 11, 2025 | tipranks.comVanguard Group Acquires Substantial Stake in Mesoblast LimitedJune 5, 2025 | tipranks.comMesoblast Limited Announces Substantial Holding UpdateJune 3, 2025 | tipranks.comMesoblast Secures Seven-Year FDA Orphan-Drug Exclusivity for Ryoncil®May 14, 2025 | tipranks.comJPMorgan Acquires Substantial Stake in Mesoblast LimitedMay 13, 2025 | tipranks.comJPMorgan Ceases Substantial Holding in Mesoblast LimitedMay 8, 2025 | tipranks.comState Street Corporation Ceases Substantial Holding in Mesoblast LimitedMay 7, 2025 | tipranks.comMesoblast Expands U.S. Market with Ryoncil® Launch and Advances Other TherapiesApril 30, 2025 | tipranks.comMesoblast Limited Appoints New Director Lyn CobleyApril 28, 2025 | tipranks.comMesoblast Limited Announces Director’s Interest ChangeApril 23, 2025 | tipranks.comMesoblast Expands Ryoncil Coverage to Over 100 Million US LivesApril 16, 2025 | tipranks.comMesoblast Limited Issues New Equity Securities for Employee IncentiveApril 8, 2025 | tipranks.comMesoblast Limited Announces Director’s Change in Securities InterestApril 8, 2025 | tipranks.comMesoblast Products Exempt from U.S. Tariffs, Strengthening Market PositionApril 3, 2025 | tipranks.comMesoblast Secures Medicaid Coverage for Ryoncil, Expanding Access for Pediatric PatientsMarch 30, 2025 | tipranks.comMesoblast Launches Ryoncil® in U.S. for Pediatric SR-aGvHDMarch 27, 2025 | tipranks.comMesoblast’s Ryoncil Gains Comprehensive U.S. Drug Pricing Compendia InclusionMarch 13, 2025 | tipranks.comMesoblast Director Increases Stake with ADS AcquisitionMarch 12, 2025 | tipranks.comMesoblast CEO to Present at ISCT Virtual Town Hall on Groundbreaking Cell TherapyMarch 12, 2025 | tipranks.comMesoblast Launches FDA-Approved Ryoncil® for Pediatric SR-aGvHDFebruary 26, 2025 | tipranks.comMesoblast Appoints Dr. Gregory George to Board, Strengthening Operational ExpertiseFebruary 23, 2025 | tipranks.comMesoblast Limited Announces New Director AppointmentFebruary 23, 2025 | tipranks.comMesoblast price target raised to $24 from $15 at Piper SandlerFebruary 8, 2025 | markets.businessinsider.comChange in Substantial Holder Interests at Mesoblast LimitedFebruary 6, 2025 | tipranks.comMesoblast Launches Ryoncil® in U.S. for Pediatric Graft-Versus-Host DiseaseJanuary 30, 2025 | tipranks.comMesoblast Limited Quotes New Securities on ASXJanuary 24, 2025 | tipranks.comMesoblast Boosts Capital with New Share IssuanceJanuary 24, 2025 | tipranks.comMesoblast Limited Announces Quotation of New SecuritiesJanuary 22, 2025 | tipranks.comMesoblast Limited Completes Strategic Share PlacementJanuary 22, 2025 | tipranks.comJPMorgan Chase & Co. Ceases Substantial Holding in Mesoblast LimitedJanuary 21, 2025 | tipranks.comBell Potter Remains a Buy on Mesoblast Limited (MEOBF)January 20, 2025 | markets.businessinsider.comMesoblast Director Increases Stake in CompanyJanuary 20, 2025 | tipranks.comMesoblast Limited Announces Major Share Issuance to Institutional InvestorsJanuary 19, 2025 | tipranks.comMesoblast Substantial Holding Changes Signal Institutional Strategy ShiftJanuary 16, 2025 | tipranks.comMesoblast Issues Unquoted Equity Securities for Employee IncentivesJanuary 16, 2025 | tipranks.comMesoblast Incentivizes Employees with Unquoted Equity IssuanceJanuary 15, 2025 | tipranks.comMesoblast Limited Announces Issuance of Unquoted Equity SecuritiesJanuary 15, 2025 | tipranks.comMesoblast Limited Announces Cessation of SecuritiesJanuary 15, 2025 | tipranks.comMesoblast Limited to Quote 7.2 Million New Securities on ASXJanuary 15, 2025 | tipranks.comMesoblast Secures A$260 Million for Ryoncil LaunchJanuary 13, 2025 | tipranks.comMesoblast Limited Announces Quotation of New Securities on ASXJanuary 10, 2025 | tipranks.com Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MEOBF and its competitors with MarketBeat's FREE daily newsletter. Email Address MEOBF Media Mentions By Week MEOBF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MEOBF News Sentiment▼-0.450.47▲Average Medical News Sentiment MEOBF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MEOBF Articles This Week▼11▲MEOBF Articles Average Week Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MEOBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Ainos News Algernon Pharmaceuticals News Allstar Health Brands News AstraZeneca News AVAX Technologies News BriaCell Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MEOBF) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access